An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

Taro Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Plaque Psoriasis

Treatments: Drug: DSXS topical

Study type: Interventional

Funder types: Industry

Identifiers

NCT02932878

DSXS 1503a

Details and patient eligibility

About

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Full description

To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to moderate plaque psoriasis.

To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to patients with mild to moderate plaque psoriasis.

Enrollment: 16 patients

Sex: All

Ages: 2 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or non pregnant, non lactating females

Exclusion criteria

• Patients under 2 years of age

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

DSXS topical

Experimental group

Description:

administered twice daily for 28 days

Treatment:

Drug: DSXS topical